Roslin Technologies posts patent application for world leading animal stem-cell technology
Roslin Technologies, the UK’s specialist AgTech venture builder, is working with stem cell patent experts Schlich Ltd (www.schlich.co.uk), to secure patent protection for its advances in the development of farm and companion animal stem cells.
Our work under our Animal Cells’ platform focuses on what are known as induced pluripotent stem cells, building on over a decade’s research on human stem cell technology. Roslin Technologies are developing this technology in key livestock and companion animal species.
“This work is a significant milestone on the road to harnessing a powerful technology in animals, allowing us to develop advanced cell therapies, drug screening assays and advanced genetic therapeutics in animals,” said Dr Mee. “Advanced animal stem cell technologies will also be a major driver in the cultured meat industry aimed to help address the world’s protein production needs.”
The Roslin Technologies approach uses an extra-chromosomal process to generate stem cells without damaging host cell DNA. Sequencing analysis of the resulting stem cells shows that we have managed to convert primary animal cells to now more pliable animal stem cells. Moreover, we have demonstrated that these new stem cells have the capacity to make different types of cells of the animal they were derived from.
Now that we have validated the platform, we are engaged in further research applicable in a range of initiatives. For example, we are working on our pig stem cells in the areas of cultured meat, drug screening assay development and novel genetic approaches to disease. For our dog stem cell platform, we are focusing on cellular and genetic therapies to alleviate disease in companion animals.
Roslin Technologies works with partners around the world to develop solutions for emerging challenges in the veterinary and agricultural sectors. For more information please contact firstname.lastname@example.org.